The DOI matches its Crossref record, with a small difference in title or year; 55 of the 55 references it cites were found in a registry or an index.
Salicylate (Salsalate) in Patients With Type 2 Diabetes: A Randomized Trial
Open accessAbstract
BACKGROUND: Short-duration studies show that salsalate improves glycemia in type 2 diabetes mellitus (T2DM). OBJECTIVE: To assess 1-year efficacy and safety of salsalate in T2DM. DESIGN: Placebo-controlled, parallel trial; computerized randomization and centralized allocation, with patients, providers, and researchers blinded to assignment. (ClinicalTrials.gov: NCT00799643). SETTING: 3 private practices and 18 academic centers in the United States. PATIENTS: Persons aged 18 to 75 years with fasting glucose levels of 12.5 mmol/L or less (≤225 mg/dL) and hemoglobin A1c (HbA1c) levels of 7.0% to 9.5% who were treated for diabetes. INTERVENTION: 286 participants were randomly assigned (between January 2009 and July 2011) to 48 weeks of placebo (n = 140) or salsalate, 3.5 g/d (n = 146), in addition to current therapies, and 283 participants were analyzed (placebo, n = 137; salsalate, n = 146). MEASUREMENTS: Change in hemoglobin A1c level (primary outcome) and safety and efficacy measures. RESULTS: The mean HbA1c level over 48 weeks was 0.37% lower in the salsalate group than in the placebo group (95% CI, -0.53% to -0.21%; P < 0.001). Glycemia improved despite more reductions in concomitant diabetes medications in salsalate recipients than in placebo recipients. Lower circulating leukocyte, neutrophil, and lymphocyte counts show the anti-inflammatory effects of salsalate. Adiponectin and hematocrit levels increased more and fasting glucose, uric acid, and triglyceride levels decreased with salsalate, but weight and low-density lipoprotein cholesterol levels also increased. Urinary albumin levels increased but reversed on discontinuation; estimated glomerular filtration rates were unchanged. LIMITATION: Trial duration and number of patients studied were insufficient to determine long-term risk-benefit of salsalate in T2DM. CONCLUSION: Salsalate improves glycemia in patients with T2DM and decreases inflammatory mediators. Continued evaluation of mixed cardiorenal signals is warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“with weight loss a greater proportion of subjects achieved either partial or complete diabetes remission134”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [134]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inflammation and insulin resistance
Shoelson, S. E. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29069 · Cited by 4,769
Self-citationMutation of the mouse klotho gene leads to a syndrome resembling ageing
Kuro-o, M., Matsumura, Y., Aizawa, H., Kawaguchi, H., Suga, T., Utsugi, T., Ohyama, Y., Kurabayashi, M., Kaname, T., Kume, E., et al. (1997) · Nature · doi:10.1038/36285 · Cited by 3,837
Type 2 diabetes as an inflammatory disease
Donath, M. Y., & Shoelson, S. E. (2011) · Nature Reviews Immunology · doi:10.1038/nri2925 · Cited by 3,737
Self-citationUric Acid and Cardiovascular Risk
Feig, D. I., Kang, D., & Johnson, R. J. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0800885 · Cited by 2,467
Yuan, M., Konstantopoulos, N., Lee, J., Hansen, L., Li, Z.-W., Karin, M., & Shoelson, S. E. (2001) · Science · doi:10.1126/science.1061620 · Cited by 1,884
Self-citationInterleukin-1-receptor antagonist in type 2 diabetes mellitus
Larsen, C. M., Faulenbach, M., Vaag, A., Vølund, A., Ehses, J. A., Seifert, B., Mandrup-Poulsen, T., & Donath, M. Y. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065213 · Cited by 1,798
Inhibition of NF-κB by Sodium Salicylate and Aspirin
Kopp, E. B., & Ghosh, S. (1994) · Science · doi:10.1126/science.8052854 · Cited by 1,744
The anti-inflammatory agents aspirin and salicylate inhibit the activity of IκB kinase-β
Yin, M.-J., Yamamoto, Y., & Gaynor, R. B. (1998) · Nature · doi:10.1038/23948 · Cited by 1,596
IKKβ/NF-κB Activation Causes Severe Muscle Wasting in Mice
Cai, D., Frantz, J. D., Tawa, N. E., Melendez, P. A., Oh, B.-C., Lidov, H. G. W., Hasselgren, P.-O., Frontera, W. R., Lee, J., Glass, D. J., et al. (2004) · Cell · doi:10.1016/j.cell.2004.09.027 · Cited by 1,367
Self-citationSchmidt, M. I., Duncan, B. B., Sharrett, A. R., Lindberg, G., Savage, P. J., Offenbacher, S., Azambuja, M. I. R., Tracy, R. P., & HEISS, G. M. (1999) · The Lancet · doi:10.1016/s0140-6736(99)01046-6 · Cited by 1,080
Research works printed but not linked: 6
- Faghihimani E, 2011, Acta Diabetol
- Vis M, 2005, J Rheumatol, 32, 252
- Ryan J, 1986, Arthritis Rheum, 29, S103
- Sweeney JD, 1988, Blood, 72, 311A
- Roth S, 1990, Semin Arthritis Rheum, 19, 11
- Lanza F, 1989, J Rheumatol, 16, 1570
Cited by
Sorted by citations
Items 201–249 of 249
ATIC as a link between antirheumatic drugs and regulation of energy metabolism in skeletal muscle
Dolinar, K. (2020) · Periodicum Biologorum · doi:10.18054/pb.v121-122i3-4.10802 · Cited by 2
Next-Generation Therapies for Type 2 Diabetes Mellitus
Patra, D., Roy, S., Ramprasad, P., & Pal, D. (2024) · Smart nanomaterials technology · doi:10.1007/978-981-99-6597-7_13 · Cited by 2
Renal Toxicity Associated with Salsalate in Elderly Adults with Anemia
Cohen, H. J., Walston, J. D., Rao, S. V., Schrier, S. L., & Artz, A. S. (2016) · Journal of the American Geriatrics Society · doi:10.1111/jgs.14065 · Cited by 2
Non-steroidal Anti-inflammatory Drugs: Overview
Day, R. O., & Graham, G. G. (2016) · Compendium of Inflammatory Diseases · doi:10.1007/978-3-7643-8550-7_52 · Cited by 2
Nakajima, V. M., Ruviaro, A. R., Barbosa, P. D. P. M., da Silva, I. F., & de Ávila, A. R. A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816992-6.00007-3 · Cited by 2
High-Sensitivity C-Reactive Protein
Feldman, D. I., Blumenthal, R. S., & Gluckman, T. J. (2022) · Contemporary cardiology · doi:10.1007/978-3-030-98824-1_17 · Cited by 2
Stafeev, I., Yudaeva, A., Michurina, S. S., Menshikov, M. Y., Shestakova, M. V., & Parfyonova, Y. V. (2023) · Diabetes Mellitus · doi:10.14341/dm12982 · Cited by 2
Ahmed, R., de Souza, R. J., Li, V., & Anand, S. S. (2022) · medRxiv · doi:10.1101/2022.06.28.22275821 · Cited by 3
Liu, P., Shang, J., Luo, D., & Shi, L. (2023) · Research Square · doi:10.21203/rs.3.rs-2487403/v1 · Cited by 3
Donath, M. Y. (2021) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2021.07.010 · Cited by 1
Abe, T., Xu, S., Sugiura, Y., Arima, Y., Hayasaka, T., Lee, M., Ishimoto, T., Araki, Y., Ngurari, S., Niu, Z., et al. (2025) · Diabetes · doi:10.2337/db25-0106 · Cited by 1
Issa, A., Badaineh, B., Al-Rawashdeh, H. F., Alomari, Y. A., Hamdan, M. Q., Al-Samarat, F., Al-Ajlouni, J. M., & Bustanji, Y. K. (2026) · Injury · doi:10.1016/j.injury.2026.113298 · Cited by 1
Bloomgarden, Z. T. (2015) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2015.02.001 · Cited by 1
Cardiovascular safety of oral antidiabetic medications: Need of the hour
Kaduskar, P. (2017) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_47_17 · Cited by 1
(2015) · Elsevier eBooks · doi:10.1016/b978-0-444-53717-1.01431-1 · Cited by 1
Metabolic Mechanisms in Diabetic Neuropathy
Yorek, M. A. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-15613-7_15 · Cited by 1
Kumbhar, N., Aparna, M. A., Nimal, S. K., Shewale, P., Barale, S. S., & Gacche, R. N. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-15232-0.00021-7 · Cited by 1
Diabetes and Mental Health: From Distress to Depression
Heinze, G., Guízar-Sánchez, D., & Bernard-Fuentes, N. (2019) · Springer eBooks · doi:10.1007/978-3-030-11815-0_26 · Cited by 1
Adipose Tissue and Immuno-Metabolic Regulation
Davanzo, G. G., Hoffman, A., Moraes‐Vieira, P. M., & Becker, L. (2021) · Springer eBooks · doi:10.1007/978-3-030-86684-6_10 · Cited by 1
High-Sensitivity C-Reactive Protein
David I. Feldman, Blumenthal, R. S., & Gluckman, T. J. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00008-x · Cited by 1
Graham, G. G., & Day, R. O. (2016) · Encyclopedia of Inflammatory Diseases · doi:10.1007/978-3-0348-0620-6_62-3 · Cited by 1
Non-steroidal Anti-inflammatory Drugs: Overview
Day, R. O., & Graham, G. G. (2016) · Encyclopedia of Inflammatory Diseases · doi:10.1007/978-3-0348-0620-6_52-4 · Cited by 1
Abe, T., Xu, S., Sugiura, Y., Arima, Y., Hayasaka, T., Lee, M., Ishimoto, T., Araki, Y., Ngurari, S., Niu, Z., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.06.24.600540 · Cited by 1
Pathophysiologie und Prävention des Typ-2-Diabetes
Martin, S. (2015) · Der Diabetologe · doi:10.1007/s11428-015-1340-y
Morris, J. S., Glynn, L. G., Murphy, A. W., Fahey, T. P., Smyth, M., & Tummon, O. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011500
Kirkland, J. L., & Tchkonia, T. (2015) · Springer eBooks · doi:10.1007/978-3-319-23246-1_19
Leung, J. Y. T. (2015) · cIRcle (University of British Columbia) · doi:10.14288/1.0166166
Recent Developments in Diabetes Therapy
Sen, S., Chakraborty, R., & De, B. (2016) · Springer eBooks · doi:10.1007/978-981-10-1542-7_12
Salsalate Improves Glycemic Control in Type 2 Diabetes
Moloo, J. (2013) · Journal watch · doi:10.1056/nejm-jw.na31850
Mechanisms By Which Glucose Lowering Therapies Reduce Obesity And Atherosclerosis
Day, E. A. (2020) · MacSphere (McMaster University) · doi:10.71548/25269
A possible Role of Salicylates in Diabetes Type II
Shehata, Y. M., Ahmed, A. I., & Nasr, N. (2020) · Zagazig Veterinary Journal/Zagazig Veterinary Journal (Online) · doi:10.21608/zvjz.2019.18354.1087
Glandt, M., & Bloomgarden, Z. T. (2016) · Springer eBooks · doi:10.1007/978-3-319-20797-1_48-1
Glandt, M., & Bloomgarden, Z. T. (2017) · Springer eBooks · doi:10.1007/978-3-319-18741-9_48
Inflammatory Pathways Linked to β Cell Demise in Diabetes
Imai, Y., Morris, M. A., Dobrian, A. D., Taylor, D., & Nadler, J. L. (2014) · Springer eBooks · doi:10.1007/978-94-007-6686-0_30
Graham, G. G., & Day, R. O. (2013) · Encyclopedia of Inflammatory Diseases · doi:10.1007/978-3-0348-0620-6_62-2
Graham, G. G., & Day, R. O. (2016) · Compendium of Inflammatory Diseases · doi:10.1007/978-3-7643-8550-7_62
Diabetes and Mental Health: From Distress to Depression
Heinze-Martin, G., Guizar, D. P., & Bernard, N. (2023) · Springer eBooks · doi:10.1007/978-3-031-25519-9_29
Pancreatic Islet Adaptation and Failure in Obesity
Imai, Y., Ladiki, D. E., & Peachee, S. J. (2023) · Springer eBooks · doi:10.1007/978-3-319-12125-3_27-3
Ridker, P. M. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-28786-9.00031-1
(2021) · American Diabetes Association eBooks · doi:10.2337/9781580407625.ch04
Salsalate improves the anti-tumor efficacy of lenvatinib in MASH-driven hepatocellular carcinoma
Tsakiridis, E. E., Ahmadi, E., Gautam, J., She, Y. R. H., Fayyazi, R., Lally, J., Wang, S. J. H., Pastena, F. D., Valvano, C. M., Rosso, D. D., et al. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101354
Is intervening inflammatory pathways a way to treat type 2-diabetes
Pareek, A. K., Nikam, S., & Akolekar, R. (2025) · International Journal of Basic & Clinical Pharmacology · doi:10.18203/2319-2003.ijbcp20251074
Anti-inflammatory Bowel Diseases Drugs and Cardiovascular Toxicity
Maličević, U., & Agrawal, D. K. (2025) · Advances in biochemistry in health and disease · doi:10.1007/978-3-031-90598-8_13
Atypical involvement of Alzheimer’s tau proteins in diseases beyond tauopathies
Meng, J., Deng, Z., Zhang, J., Yu, W., Wu, X., & Lei, P. (2026) · Life Medicine · doi:10.1093/lifemedi/lnag016
Alqarni, A., Al-Kuraishy, H. M., Alqarni, M. A., Eliwa, D., Al-Gareeb, A. I., Bahaa, M. M., & Batiha, G. E. (2026) · Immunological Investigations · doi:10.1080/08820139.2026.2704902
Molecular and Cellular Crosstalk in the Pathogenesis of Diabetic Retinopathy
Sadikan, M. Z., & Nasir, N. A. A. (2026) · Archives of Medical Science · doi:10.5114/aoms/220653
Orphan GPCRs in diabetes mellitus: metabolic control, inflammation, and drug development
Sureka, C., Muniyandi, V., Geddawy, A., Ramesh, T., Murugesan, A., & Kandhavelu, M. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1916297
Li, T., Danilova, I. G., Rakhov, I. A., & Sokolova, K. V. (2026) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-026-02084-2
Metadata
- Authors
- Goldfine, A. B., Fonseca, V., Jablonski, K. A., Chen, Y.-D. I., Tipton, L., Staten, M. A., & Shoelson, S. E.
- Affiliations
- Tulane University (US)
- Corresponding author
- Shoelson, Steven E.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2013-07-02
- Volume
- 159
- Issue
- 1
- Pages
- 1-12
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- PMC
- PMC4128629
- OpenAlex
- W2031980199
- Cited by
- 251
- References
- 55
- Citations by year
- 2026: 6 · 2025: 11 · 2024: 12 · 2023: 14 · 2022: 10 · 2021: 16 · 2020: 19 · 2019: 19 · 2018: 12 · 2017: 20 · 2016: 38 · 2015: 31 · 2014: 28 · 2013: 15
- FWCI
- 29.20
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (UL1TR000124, UL1TR000454, 5p50hl083813-05)
- National Heart, Lung, and Blood Institute (P50 HL83813, P50-HL083813)
- National Institute of General Medical Sciences (U54GM104940)
- National Institute of Diabetes and Digestive and Kidney Diseases (RC4DK090792, U01DK074556, P30 DK03836, P30DK036836, P30DK063491)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- salsalate, type 2 diabetes, glycemic control, HbA1c, nonsteroidal anti-inflammatory drugs, anti-inflammatory activity, white blood cell count, adiponectin, uric acid, triglycerides, urinary albumin, estimated glomerular filtration rate, drug safety, long-term efficacy, weight gain
- MeSH terms
- Adolescent, Adult, Aged, Anti-Inflammatory Agents, Non-Steroidal, Blood Glucose, Diabetes Mellitus, Type 2, Female, Glycated Hemoglobin, Humans, Kidney, Male, Middle Aged, Salicylates, Single-Blind Method, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
